2 Companies With Game-Changing Oncology Platforms
For the past couple of years, the biotechnology industry has been the hottest sector as companies continue to come up with unique, innovative ways to treat unmet medical needs. In particular, investors have focused their attention on companies developing innovative technology in an effort to treat various forms of cancer. Once considered an impossible area to make much of a difference, two companies are on the verge of creating hope for millions. Those two companies that investors should take a close look at are Halozyme Therapeutics (NASDAQ:HALO) and Lion Biotechnologies (LBIO.OB).
Halozyme Therapeutics is a biopharmaceutical company developing and commercializing recombinant human enzymes to provide enhanced and innovative products that improve the practice of medicine. The company has developed a pipeline focused on developing treatments in the fields of diabetes, oncology, dermatology, and drug delivery markets.
The company’s platform is based upon its recombinant human hyaluronidase enzyme, rHuPH20, which temporarily degrades hyaluronan, a structural protein in the interstitial space. The temporary degradation provides an opportunity for the injection of biologics such as monoclonal antibodies, as well as small molecules and fluids. Halozyme’s enzyme, rHuPH20, allows many pharmaceuticals to be injected subcutaneously instead of intravenously. Subcutaneous administration provides several benefits over intravenous injection such as patient convenience, reduction of infusion reactions, shorter administration time, lower administration costs, and life cycle management.
Over the past six months, Halozyme Therapeutics has been one of the hottest stocks in the biotechnology industry. The company has nearly doubled its market capitalization, which is currently at approximately $1.87 billion. The primary reason for the large value increase is the strength of the company’s proprietary products as well as its collaboration products. Halozyme has developed partnerships with Roche (RHHBY.PK), Pfizer (NYSE:PFE), Baxter (NYSE:BAX), and Intrexon (NYSE:XON). Of those, the partnership with Roche has investors particularly excited as combination therapies have demonstrated significant potential in several research studies.